Sanofi (SNY,SAN.PA) reported that the LEAP2MONO phase 3 study demonstrated that venglustat met the primary and three out of four key secondary endpoints in adults and pediatric patients with neurological manifestations of type 3 Gaucher disease. Venglustat demonstrated superiority versus enzyme replacement therapy in addressing neurological symptoms. Also, Venglustat was well tolerated overall with no new safety signals. Sanofi said it will pursue global regulatory filings for venglustat in GD3.
Houman Ashrafian, Executive Vice President and Head of Research and Development at Sanofi, said: "What excites us most is the potential to address critical unmet medical needs. A daily pill could make a serious difference for Gaucher patients facing neurological challenges."
Sanofi shares are trading at 79.20 euros, up 2.75%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
January 30, 2026 15:51 ET The Federal Reserve policy decision was the main event in the final week of January, which saw a heavy flow of economics news. Several data reflecting the trends in the U.S. economy were also released during the week. The interest rate decision from Canada also was in focus. In Europe, economic sentiment data gained attention. The policy decision from Singapore was the highlight in Asia.